Mumbai, Feb. 20 -- As per the regulatory filing, the USFDA conducted an inspection at one of Aurobindo Pharma USA Inc.'s warehouses, located in East Windsor, New Jersey, from 13 May to 15 May 2024. The inspection focused on the company's compliance with the Drug Supply Chain Security Act (DSCSA) and concluded with five observations.

Subsequently, the US FDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated (OAI)'.

Despite these findings, Aurobindo Pharma stated that it does not foresee any significant impact on its business operations. The company emphasized its commitment to working closely with the USFDA and enhancing compliance measures on an ongoing basis.

Aurobindo Pharm...